Studies consistently show that weight regain begins soon after stopping medication and is proportional to the amount of weight originally lost: Semaglutide (Wegovy) : In the STEP 1 extension study, participants who lost an average of 17% of their body weight regained approximately two-thirds of that weight within one year of stopping the medication
Studies from the STEP program and real-world registries show semaglutide is safe for years of continuous therapy at stable or maintenance doses
Focal APC is uncontrolled, and no studies have documented a consistent depth of burn
While the risk of severe adverse reactions from these byproducts is considered low in properly sealed medication, it is not zero
Methods The SCALE Kids (NCT04775082), a phase 3a, double-blind, randomized, placebo-controlled trial, investigated the efficacy and safety of liraglutide, as an adjunct to lifestyle interventions, compared to placebo in children ages six to less than 12 years old